The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NSABP FC-10: Phase IB study of pembrolizumab in combination with premetrexed + oaliplatin in patients (pts) with chemo-refractory metastatic colorectal cancer (mCRC).
 
James J. Lee
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Incyte; Incyte; Incyte; Incyte; Loxo; Loxo; Loxo; Loxo
Research Funding - Merck; Merck; Merck; Merck
 
Greg Yothers
Employment - Mountainview Pediatrics (I); Mountainview Pediatrics (I); Mountainview Pediatrics (I); Mountainview Pediatrics (I)
Consulting or Advisory Role - Orbus Therapeutics; Orbus Therapeutics; Orbus Therapeutics; Orbus Therapeutics; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics
 
Thomas J. George
Consulting or Advisory Role - Bayer/Onyx; Bayer/Onyx; Bayer/Onyx; Bayer/Onyx; Merck; Merck; Merck; Merck
Research Funding - AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer/Onyx (Inst); Bayer/Onyx (Inst); Bayer/Onyx (Inst); Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst)
 
John C. Krauss
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); ACCRU (Inst); ACCRU (Inst); ACCRU (Inst); ACCRU (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Ignyta (Inst); Ignyta (Inst); Ignyta (Inst); Ignyta (Inst); Isofol Medical (Inst); Isofol Medical (Inst); Isofol Medical (Inst); Isofol Medical (Inst); NSABP Foundation (Inst); NSABP Foundation (Inst); NSABP Foundation (Inst); NSABP Foundation (Inst); OncoMed (Inst); OncoMed (Inst); OncoMed (Inst); OncoMed (Inst); Shire (Inst); Shire (Inst); Shire (Inst); Shire (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); XBiotech (Inst); XBiotech (Inst); XBiotech (Inst); XBiotech (Inst)
 
Bassam Nabih Maalouf
No Relationships to Disclose
 
Hiral D. Parekh
No Relationships to Disclose
 
Anuradha Krishnamurthy
No Relationships to Disclose
 
Kelly R. Vehec
No Relationships to Disclose
 
Norman Wolmark
Research Funding - AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); NSABP Foundation (Inst); NSABP Foundation (Inst); NSABP Foundation (Inst); NSABP Foundation (Inst)
Travel, Accommodations, Expenses - Genentech; Genentech; Genentech; Genentech
 
Carmen Joseph Allegra
No Relationships to Disclose
 
Samuel A. Jacobs
No Relationships to Disclose